混合配体Cu（II）腙复合物设计用于增强其抗癌活性文献综述

文献综述

铂类药物(如顺铂及其第二代和第三代类似物)虽然在治疗各种实体肿瘤方面非常有效，但仍受到剂量限制副作用和遗传或获得性耐药的限制。这些缺点促使化学家们发现基于内源性金属的替代化疗策略，这些策略具有更好的药理特性。在生物必需金属中，铜存在于所有生物体内，可作为催化和结构辅助因子;因此，它在氧化还原化学、发育和生长途径中具有关键作用。铜在血管生成中起着核心作用，血管生成是肿瘤生长、侵袭和转移的关键过程。许多研究报告指出，许多癌组织，如乳腺癌、脑癌和前列腺癌组织，比正常组织吸收更多的铜。因此，铜配合物被认为是铂类抗癌药物的有前途的替代品，近年来各种铜基抗癌药物被研究作为潜在的抗癌药物。

参考文献：

[1] Y. Jung, S.J. Lippard, Direct cellular responses to platinum-induced DNA damage, Chem. Rev. 107 (2007) 1387e1407.[2] M.A. Fuertes, C. Alonso, J.M. Perez, Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance, Chem. Rev. 103 (2003) 645e662.[3] P.C.A. Bruijnincx, P.J. Sadler, New trends for metal complexes with anticancer activity, Curr. Opin. Chem. Biol. 12 (2008) 197e206.[4] C. Stefani, Z. Al-Eisawi, P.J. Jansson, D.S. Kalinowski, D.R. Richardson, Identi- fication of differential anti-neoplastic activity of copper bis(thiosemicarba- zones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization, J. Inorg. Biochem. 152 (2015) 20e37.[5] C. Santini, M. Pellei, V. Gandin, M. Porchia, F. Tisato, C. Marzano, Advances in copper complexes as anticancer agents, Chem. Rev. 114 (2014) 815e862.[6] S.B. Chanu, S. Banerjee, M. Roy, Potent anticancer activity of photo-activatedoxo-bridged diiron(III) complexes, Eur. J. Med. Chem. 125 (2017) 816e824.[7] L. Ruiz-Azuara, M.E. Bravo-Gomez, Copper compounds in cancer chemo-therapy, Curr. Med. Chem. 17 (2010) 3606e3615.[8] B. Hassouneh, M. Islam, T. Nagel, Q. Pan, S.D. Merajver, T.N. Teknos, Tetra-thiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer, Mol. Canc. Therapeut. 6 (2007) 1039e1045.[9] M.M. Eatock, A. Schatzlein, S.B. Kaye, Tumour vasculature as a target for anticancer therapy, Canc. Treat Rev. 26 (2000) 191e204.[10] H.Xie,Y.J.Kang,Roleofcopperinangiogenesisanditsmedicinalimplications, Curr. Med. Chem. 16 (2009) 1304e1314.[11] A.Gupte,R.J.Mumper,Elevatedcopperandoxidativestressincancercellsasa target for cancer treatment, Canc. Treat Rev. 35 (2009) 32e46.[12] F. Tisato, C. Marzano, M. Porchia, M. Pellei, C. Santini, Copper in diseases and treatments, and copper-based anticancer strategies, Med. Res. Rev. 30 (2010) 708e749.[13] T.B. Chaston, R.N. Watts, J. Yuan, D.R. Richardson, Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation, Clin. Canc. Res. 10 (2004) 7365e7374.[14] X. Bao, Y. Xue, C. Xia, Y. Lu, N. Yang, Y. Zhao, Synthesis and assessment of novel anti-chlamydial benzylidene acylhydrazides derivatives, Lett. Drug Des. Discov. 15 (2018) 31e36.[15] K. Hruskova , E. Pot#uckova , T. Hergeselova , L. Lipta kova , P. Haskova , P. Mingas, P. Kovarikova , T. Sim#unek, K. Va vrov a, Aroylhydrazone iron chelators: tuning antioxidant and antiproliferative properties by hydrazide modifications, Eur. J. Med. Chem. 120 (2016) 97e110.[16] B. Samanta, J. Chakraborty, S. Shit, S.R. Batten, P. Jensen, J.D. Masuda, S. Mitra, Synthesis, characterisation and crystal structures of a few coordination complexes of nickel(II), cobalt(III) and zinc(II) with N0-[(2-pyridyl)methylene] salicyloylhydrazone Schiff base, Inorg. Chim. Acta. 360 (2007) 2471e2484.

资料编号：[676012]